Why Novavax Has Limited Downside from Here

InvestorPlace2022-02-21

Investors may almost forgive Novavax(NASDAQ:NVAX) for seeking approval for its coronavirus vaccine late. Traders are happy that NVAX stock rose alongside that of Moderna(NASDAQ:MRNA),Pfizer(NYSE:PFE),...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • Kerrisdale
    2022-02-22
    Kerrisdale
    Also agreed vaccine markets are quite saturated, but due to high prices, many poorer countriesdo not have adequate access and supplies.. if they can't pay , then less revenues. Hope for cheaper vaccines.
  • RO8
    2022-02-22
    RO8
    Yes
  • Frosty4ever
    2022-02-22
    Frosty4ever
    Omicron sub variant is here. More transmissible and initial fear is more deadly. Large part of the world still aren't vaxx yet. 
  • vivienne249
    2022-02-22
    vivienne249
    What else is in the pipeline? Vaccine market is quite saturated 
  • ACCY
    2022-02-21
    ACCY
    At least it is non-mRNA! That's a plus point 👍
  • aaronh
    2022-02-21
    aaronh
    [smile] 
Leave a comment
9